• Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

    Source: Nasdaq GlobeNewswire / 04 May 2023 07:00:01   America/New_York

    – European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 –

    – Completion of ONC206 Dose Escalation Expected by First Half 2024 –

    – Conference Call at 8:30 a.m. ET Today –

    DURHAM, N.C., May 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an operational update.

    “2023 is off to a strong start and has been highlighted by multiple presentations of data in support of our imipridone platform during the recent American Association for Cancer Research Annual Meeting (AACR) and our sponsorship at the Canadian Neuro-Oncology Meeting (CNO) this week,” said Mike Sherman, Chief Executive Officer of Chimerix. “Dr. Carl Koschmann’s ONC201 presentation at AACR marks the first known example of any therapy reversing the H3 K27 trimethyl loss (H3 K27me3-loss) seen in H3 K27M-mutant glioma patients. This shows that dordaviprone (ONC201) can reverse the epigenetic signature which is thought to be a defining characteristic of the disease. Recent literature suggests that reversing the H3 K27M mutation that increases H3 K27 trimethylation in established tumor models results in significant antitumor effects and prolongation of survival. This finding provides additional objective evidence of ONC201 biological activity in this patient population to complement the tumor response observed in the Phase 2 clinical studies. We have also recently completed multiple clinical pharmacology studies, the findings of which have been consistent with our expectations. These studies comprise key elements of a future new drug application (NDA) for ONC201 following positive data from the ACTION study. Our focus has been on accelerating every aspect possible of the Phase 3 ACTION study in order to expedite patient access to this potentially life-altering drug. To that end, we have now received authorization for the ACTION study from nine countries including the United States, the United Kingdom, South Korea, Israel and key markets across Western Europe, as our ramp of site activations continues."

    “In addition, we are making good progress advancing the Phase 1 dose escalation studies for our second generation compound, ONC206. As these are open-label studies, in addition to the previously announced objective response observed to ONC206 monotherapy, we hope to identify additional signals of activity this year and look forward to completing dose escalation by first half of 2024,” added Mr. Sherman.

    ONC201 for Treatment of H3 K27M-Mutant Diffuse Glioma

    In April, Chimerix and along with collaborators presented multiple datasets related to the imipridone platform at the AACR Annual Meeting in Orlando, FL. Key results presented by collaborators at the University of Michigan demonstrated that H3 K27M-mutant glioma patients treated with ONC201 experienced a statistically significant reversal of the H3 K27me3-loss epigenetic signature throughout their tumor compared to patients who did not receive ONC201. Gliomas with the H3 K27M-mutation undergo H3 K27me3-loss, which is a negative prognostic variable among gliomas and thought to be a defining characteristic of the disease. Concordant findings were also reported in preclinical models that were mechanistically linked to specific metabolic changes induced in tumors by ONC201.

    Ongoing Development of ONC206

    ONC206 is a second generation, potentially differentiated imipridone DRD2 antagonist and ClpP agonist, that has demonstrated monotherapy anti-cancer activity in pre-clinical models. ONC206 is currently being evaluated in Phase I dose escalation trials enrolling patients with advanced central nervous system tumors. In March 2023, the Company reported an investigator-assessed response that emerged during dose escalation in the PNOC study. The responder is a patient with recurrent glioblastoma without the H3K27M-mutation who received ONC206 monotherapy.  

    Preclinical work is ongoing that is designed to further elucidate the ONC206 mechanism of action, identify potential pharmacodynamic biomarkers, and assess the monotherapy efficacy profile of ONC206 in tumors that do not harbor the H3K27M mutation. These activities will inform data-driven clinical development plans.

    First Quarter 2023 Financial Results

    Chimerix reported a net loss of $21.4 million, or $0.24 per basic and diluted share, for the first quarter of 2023. During the same period in 2022, Chimerix recorded a net loss of $24.8 million, or $0.28 per basic and diluted share.

    Research and development expenses decreased to $18.8 million for the first quarter of 2023, compared to $19.0 million for the same period in 2022.

    General and administrative expenses increased to $5.7 million for the first quarter of 2023, compared to $5.6 million for the same period in 2022.

    Chimerix's balance sheet at March 31, 2023 included $246.1 million of capital available to fund operations, approximately 88.6 million outstanding shares of common stock and no outstanding debt.

    Conference Call and Webcast

    Chimerix will host a conference call and live audio webcast to discuss first quarter 2023 financial results and provide a business update today at 8:30 a.m. ET. To access the live conference call, please dial 646-307-1963 (domestic) or 800-715-9871 (international) at least five minutes prior to the start time and refer to conference ID 8594205.

    A live audio webcast of the call will also be available on the Investors section of Chimerix’s website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

    About the Phase 3 ACTION Study

    The ACTION study is a worldwide, randomized, double-blind, placebo-controlled, multicenter study of ONC201 designed to enroll 450 newly diagnosed diffuse glioma patients whose tumor harbors an H3 K27M-mutation. Treatment with ONC201 begins shortly after completion of radiation therapy. Participants are randomized 1:1:1 to receive 625mg of ONC201 once per week (the Phase 2 dosing regimen), 625mg twice per week on two consecutive days or placebo. The dose is scaled by body weight for pediatric patients. Overall survival (OS) will be assessed for efficacy at three alpha-allocated timepoints: two interim assessments by the Independent Data Monitoring Committee (IDMC) at 164 events and 246 events, respectively, and a final assessment at 327 events. The final Progression Free Survival analysis will be performed after 286 events, with progression assessed using RANO HGG criteria by blinded independent central review (BICR).

    About Chimerix

    Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the probability of success of the Phase 3 ACTION study, the potential filing and approval of and NDA for ONC201 and subsequent commercial opportunity, the implications of the monotherapy radiographic partial response observed during ONC206 dose escalation; the ability to reproduce clinical and pre-clinical findings, and projections regarding funding and timing of future data readouts. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks related to the timing, completion and outcome of the Phase 3 ACTION study of ONC201; risks associated with repeating positive results obtained in prior preclinical or clinical studies in future studies; risks related to the clinical development of ONC206; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

    CONTACTS:

    Michelle LaSpaluto
    919 972-7115
    ir@chimerix.com

    Will O’Connor
    Stern Investor Relations
    212-362-1200
    will@sternir.com

     


    CHIMERIX, INC.
    CONSOLIDATED BALANCE SHEETS
    (in thousands, except share and per share data)
    (unaudited)
             
         March 31, December 31, 
          2023   2022  
    ASSETS     
    Current assets:     
     Cash and cash equivalents $15,951  $25,842  
     Short-term investments, available-for-sale  198,801   191,492  
     Accounts receivable  668   1,040  
     Prepaid expenses and other current assets  9,330   9,764  
      Total current assets  224,750   228,138  
    Long-term investments  31,322   48,626  
    Property and equipment, net of accumulated depreciation  267   227  
    Operating lease right-of-use assets  1,848   1,964  
    Other long-term assets  346   386  
       Total assets $258,533  $279,341  
             
    LIABILITIES AND STOCKHOLDERS' EQUITY     
    Current liabilities:     
     Accounts payable $2,847  $3,034  
     Accrued liabilities  13,584   17,381  
      Total current liabilities  16,431   20,415  
    Loan Fees  125   250  
    Lease-related obligations  1,666   1,819  
       Total liabilities  18,222   22,484  
             
    Stockholders’ equity:     
     Preferred stock, $0.001 par value, 10,000,000 shares authorized at March 31, 2023 and     
      December 31, 2022; no shares issued and outstanding as of March 31, 2023 and     
      December 31, 2022; no shares issued and outstanding as of March 31, 2023 and  -   -  
     Common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2023 and     
      December 31, 2022; 88,583,567 and 88,054,127 shares issued and outstanding as of     
      March 31, 2023 and December 31, 2022, respectively  89   88  
     Additional paid-in capital  975,254   970,535  
     Accumulated other comprehensive loss, net  (231)  (337) 
     Accumulated deficit  (734,801)  (713,429) 
      Total stockholders’ equity  240,311   256,857  
       Total liabilities and stockholders’ equity $258,533  $279,341  



    CHIMERIX, INC.
    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
    (in thousands, except share and per share data)
    (unaudited)
             
           Three Months Ended March 31,
           2023   2022 
    Revenues:    
     Contract and grant revenue $234  $- 
     Licensing revenue  49   15 
      Total revenues  283   15 
     Cost of goods sold  -   114 
      Gross Profit  283   (99)
    Operating expenses:    
     Research and development  18,822   19,040 
     General and administrative  5,679   5,632 
      Total operating expenses  24,501   24,672 
       Loss from operations  (24,218)  (24,771)
    Other income:    
     Interest income and other, net  2,846   4 
        Net loss  (21,372)  (24,767)
    Other comprehensive loss:    
     Unrealized gain (loss) on debt investments, net  106   (52)
        Comprehensive loss $(21,266) $(24,819)
    Per share information:    
     Net income (loss), basic and diluted $(0.24) $(0.28)
             
     Weighted-average shares outstanding, basic and diluted 88,294,624   87,088,804 

    Primary Logo

Share on,